Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Coya Therapeutics (COYA) over the last 4 years, with Q3 2025 value amounting to $180358.0.

  • Coya Therapeutics' Change in Account Payables rose 11210.44% to $180358.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $774980.0, marking a year-over-year increase of 36073.5%. This contributed to the annual value of $477450.0 for FY2024, which is 5978.06% up from last year.
  • According to the latest figures from Q3 2025, Coya Therapeutics' Change in Account Payables is $180358.0, which was up 11210.44% from -$758663.0 recorded in Q2 2025.
  • Coya Therapeutics' 5-year Change in Account Payables high stood at $1.3 million for Q4 2024, and its period low was -$1.5 million during Q3 2024.
  • Moreover, its 4-year median value for Change in Account Payables was $180358.0 (2025), whereas its average is $76341.6.
  • As far as peak fluctuations go, Coya Therapeutics' Change in Account Payables surged by 65403.2% in 2023, and later crashed by 47591.53% in 2024.
  • Coya Therapeutics' Change in Account Payables (Quarter) stood at $389106.0 in 2022, then grew by 22.52% to $476727.0 in 2023, then soared by 162.5% to $1.3 million in 2024, then plummeted by 85.59% to $180358.0 in 2025.
  • Its Change in Account Payables stands at $180358.0 for Q3 2025, versus -$758663.0 for Q2 2025 and $101879.0 for Q1 2025.